Aspira Women's Health Reports Second Quarter 2022 Financial Results

10.08.2022 - Increased product revenue by 17% to $2.0 million; Grew OVA1plus volume by 19% to 5,411 units Entered into a research agreement with Harvard’s Dana Farber Cancer Institute, Brigham & Women’s Hospital, and Medical University of Lodz for development ...

Related Keywords

United States ,Texas ,Nicole Sandford ,Ashleyr Robinson ,Aspira Geneti ,Office Of Aspira ,Lifesci Advisors ,Aspira Women Health ,Aspira Women Health Inc ,Drug Administration ,Harvard Dana Farber Cancer Institute ,University Of Lodz ,Nasdaq ,Dana Farber Cancer Institute ,Bioreference Laboratories Inc ,Scarlet Health ,Conference Call ,Chief Executive Office ,Operational Excellence ,Medical University ,Bioreference Laboratories ,Aspira Women ,Analytical Validation ,Deep Neural Network Algorithm ,Ovarian Cancer ,Cash Utilization ,Second Quarter ,Eastern Time ,Private Securities Litigation Reform Act ,Annual Report ,Relations Contact ,Sci Advisors ,Except Share ,Par Value Amounts ,Consolidated Statements ,Per Share Amounts ,